{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:40:33Z","timestamp":1791268833787,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.amjcard.2008.07.028","type":"journal-article","created":{"date-parts":[[2008,9,9]],"date-time":"2008-09-09T13:14:11Z","timestamp":1220966051000},"page":"1571-1576","source":"Crossref","is-referenced-by-count":8,"title":["Intensive Lipid-Lowering Therapy for Patients With Aortic Stenosis\u2020\u2020Conflicts of interest: Dr Pedersen has received research grants from Merck Sharp & Dohme, Norway; Merck\/Schering-Plough, North Wales, Pennsylvania; and Pfizer, Inc., New York, New York, and consultant honoraria and speaker's fees from Merck Sharp & Dohme; Merck\/Schering-Plough; Pfizer, Inc.; AstraZeneca, Wilmington, Delaware; and Merck KgaA, Darmstadt, Germany."],"prefix":"10.1016","volume":"102","author":[{"given":"Terje R.","family":"Pedersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2008.07.028_bib1","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1161\/CIRCULATIONAHA.106.176857","volume":"114","author":"Bonow","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2008.07.028_bib2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/CRD.0b013e31805f6796","article-title":"Valvular aortic stenosis in the elderly","volume":"15","author":"Aronow","year":"2007","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.amjcard.2008.07.028_bib3","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1161\/hc4301.098249","article-title":"Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis","volume":"104","author":"Novaro","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2008.07.028_bib4","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jacc.2006.07.072","article-title":"Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis","volume":"49","author":"Moura","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2008.07.028_bib5","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1056\/NEJMoa043876","article-title":"Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis","volume":"352","author":"Cowell","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2008.07.028_bib6","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.ahj.2007.03.011","article-title":"Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis: the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial","volume":"153","author":"Chan","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2008.07.028_bib7","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.amjcard.2006.10.064","article-title":"Design and baseline characteristics of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study","volume":"99","author":"Rosseb\u00f8","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2008.07.028_bib8","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1161\/hc4101.097527","article-title":"Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors","volume":"104","author":"Pohle","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2008.07.028_bib9","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0002-9149(01)01821-5","article-title":"Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons","volume":"88","author":"Aronow","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2008.07.028_bib10","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S0140-6736(02)08161-8","article-title":"HMG CoA reductase inhibitor (statin) and aortic valve calcium","volume":"359","author":"Shavelle","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2008.07.028_bib11","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1161\/01.CIR.0000140723.15274.53","article-title":"Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis","volume":"110","author":"Rosenhek","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2008.07.028_bib12","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/S0735-1097(02)02496-8","article-title":"Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community","volume":"40","author":"Bellamy","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2008.07.028_bib13","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.amjcard.2003.09.031","article-title":"Treating to New Targets (TNT) study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?","volume":"93","author":"Waters","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2008.07.028_bib14","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2008.07.028_bib15","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2008.07.028_bib16","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2008.07.028_bib17","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2008.07.028_bib18","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S0002-9149(99)00533-0","article-title":"The design of a prospective study of pravastatin in the elderly at risk (PROSPER)","volume":"84","author":"Shepherd","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2008.07.028_bib19","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial","volume":"291","author":"Nissen","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2008.07.028_bib20","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2008.07.028_bib21","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1053\/euhj.1998.1350","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience","volume":"20","year":"1999","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2008.07.028_bib22","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914908012605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914908012605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,26]],"date-time":"2018-12-26T01:28:53Z","timestamp":1545787733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914908012605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S0002914908012605"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2008.07.028","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}